Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

NCT04633148 is registered in ClinicalTrials.gov with AvenCell Europe GmbH as lead sponsor.

NCT NCT04633148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04633148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
Lead sponsor
AvenCell Europe GmbH
Phase
Phase 1
Overall status
Terminated
Start date
November 23, 2020
Completion date
March 28, 2024
Enrollment
16 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer